Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text

Ocular Disease, Ophthalmology, Age-related Diseases +3

Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON

Soraya Rofagha, Robert B. Bhisitkul, David S. Boyer et al. · Ophthalmology · 2013 · 995 citations

Symptomatic Treatment, Outcomes Research, Seven-year Outcomes +2

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

Anne E. Fung, Geeta A. Lalwani, Philip J. Rosenfeld et al. · American Journal of Ophthalmology · 2007 · 966 citations

Ocular Disease, Vitreous Body, Optical Coherence Tomography-guided +6